JZP 815
Alternative Names: JZP-815Latest Information Update: 28 Jan 2026
At a glance
- Originator Redx Pharma
- Developer Jazz Pharmaceuticals Inc
- Class Antineoplastics; Small molecules
- Mechanism of Action Raf kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Haematological malignancies; Solid tumours
Most Recent Events
- 28 Jan 2026 Phase-I development in Solid-tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) is ongoing in USA (PO, Capsule) (NCT05557045) (Jazz Pharmaceuticals pipeline, January 2026)
- 28 Jan 2026 Phase-I clinical trials in Haematological malignancies (PO) before January 2026 (Jazz Pharmaceuticals pipeline, January 2026)
- 28 Dec 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO, Capsule)